FORT LEE, N.J., April. 24, 2024 — Kedrion Biopharma, an international biopharmaceutical company specializing in the production and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, was prominently featured during the World Federation of Hemophilia (WFH) World Congress in Madrid from April 21 to April 24, 2024. The WFH Congress is the largest international bleeding disorders meeting annually.
“Kedrion is proud to have sponsored two Presentation Theatres and presented three posters at this important gathering. Our findings continue to showcase our commitment to raising awareness and deepening the understanding of ultra-rare bleeding disorders,” said Karen Thibaudeau, PhD, Global Medical Therapeutic Area Lead at Kedrion.
Dr. Kim Clark, PharmD, Medical Affairs and Excellence Capabilities Lead, presented two posters representing subgroup analyses from the Hereditary Factor X Deficiency in America Survey, which assessed the impacts of hereditary factor X deficiency (HFXD) on patients and caregivers. Hereditary factor X deficiency is an ultra-rare bleeding disorder that affects approximately one in 1 million people and causes unusual or excessive bleeding or bruising and, in extreme cases, can result in life-threatening complications like bleeding in the brain or stomach.
“This first of its kind survey has brought to light the everyday challenges that patients with HFXD face, and the significant hurdles physicians encounter when diagnosing this ultra-rare bleeding disorder,” Clark explained.
In addition, Kedrion partnered to facilitate presentations on identifying unmet needs in the lives of patients with HFXD and the treatment of congenital plasminogen deficiency. These presentations were led by Flora Peyvandi, President of the International Society on Thrombosis and Haemostasis (ISTH), Robert Klamroth, Past President of the European Association for Haemophilia and Allied Disorders (EAHAD), and Prof. Per Morten Sandset, MD, Vice Rector, University of Oslo, respectively.
Poster Presentations:
Safety and Efficacy of Long-Term Treatment of Type 1 Plasminogen Deficiency Patients with Intravenous Plasminogen Replacement Therapy
Presenter: Karen Thibaudeau
Burden of Disease and Impact on Quality of Life in Hereditary Factor X Deficiency Patients Who Have Experienced Menorrhagia: Findings From the Hereditary Factor X Deficiency in America Survey
Presenting Author: Dr. Kim Clark
Burden of Disease and Impact on Quality of Life in Hereditary Factor X Deficiency Patients Receiving Prophylaxis: Findings From the Hereditary Factor X Deficiency in America Survey
Presenting Author: Dr. Kim Clark